The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded an $8.9 million grant to Pulmotect for continued development of the company’s PUL-042 immune stimulating inhalation solution, the company announced. Pulmotect said that the funds will go toward a Phase 2 trial titled, “A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing Lower Respiratory Tract Complications in Patients with Hematologic Malignancies and Recipients of Hematopoietic Stem Cell Transplantation (HSCT) with Documented Viral Infections with Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV).”
In 2012, CPRIT awarded the company $7.1 million for development of PUL-042 from preclinical studies into Phase 2 for protection against pneumonia in patients undergoing chemotherapy. Pulmotect has also received funding for development of the inhalation solution from the National Heart, Lung, and Blood Institute of the National Institutes of Health and from the US Department of Defense, which provided funding to support Phase 2 development of PUL-042 for the treatment of COVID-19. In September 2021, Pulmotect announced positive results from a Phase 2 trial of PUL-042 for the treatment of COVID-19.
Pulmotect CEO Colin Broom commented, “We appreciate the extensive review and due diligence performed by CPRIT that led to this award. The award allows us to advance our Phase 2 Anti-Viral program and further develop our unique asset PUL-042.”
Read the Pulmotect press release.
